Eli Lilly and Company
Q2 2026 (reported Aug 5) — revenue $23.0B (+48%), Mounjaro $9.9B (+91%), Zepbound $4.9B (+46%), oral Foundayo $98M in its first quarter; FY2026 revenue guide raised to $85-87B. AI is a cost-side R&D bet, not revenue — an in-house NVIDIA DGX SuperPOD with 1,016 Blackwell Ultra GPUs (launched Feb 2026), an NVIDIA co-innovation lab (up to $1B over five years, announced Jan 2026), an Insilico licensing deal (up to $2.75B, $115M upfront, Mar 2026) and the Isomorphic Labs collaboration (up to $1.7B in milestones, 2024). TuneLab, the federated model-sharing platform for biotechs, added Twist Bioscience as a data partner in Sep 2026.
Scenarios
GLP-1 cash ($85-87B 2026 revenue guide) funds the largest pharma-owned AI compute and data stack, and TuneLab turns proprietary data into an ecosystem that partners feed back into. If AI shortens discovery cycles, the scale advantage compounds.
AI spend is long-cycle and still unproven in clinical outcomes, while Novo (Anthropic partnership, Sep 2026) and Roche build comparable stacks, eroding first-mover advantage. Near-term value is driven by GLP-1 volume and pricing (Q2 2026 price -13%), not AI.
Key Factors to Watch
- ●Q2 2026 (Aug 5) revenue $23.0B (+48%), FY2026 guide raised to $85-87B
- ●LillyPod — 1,016 Blackwell Ultra GPUs, >9,000 petaflops, launched Feb 2026
- ●NVIDIA co-innovation lab — up to $1B over five years (announced Jan 2026)
- ●Insilico licence up to $2.75B, $115M upfront (Mar 29, 2026); Isomorphic Labs up to $1.7B milestones (Jan 2024)
- ●TuneLab ecosystem added Twist Bioscience (Sep 16, 2026) — no disclosed financial terms
- ●Foundayo oral GLP-1 $98M in Q2 2026, launch reported lagging Novo oral Wegovy
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-10-03 | 7.8 | Positive | Rotating refresh — Q2 2026 (Aug 5) revenue $23.0B +48%, FY guide $85-87B; corrected stale $80-83B guide, Insilico scope (select candidates, not 28 molecules) and Isomorphic to $1.7B; Sep 2026 TuneLab partner adds immaterial; score held 7.8 |
| 2026-03-08 | 7.8 | Positive | Score 8.3→7.8 (are 9→7). are recalibrated: $1B NVIDIA lab + $3B Isomorphic deal are AI COSTS not AI REVENUE; revenue is GLP-1 drugs |
| 2026-03-08 | 8.3 | Very Positive | Score 8.2→8.3 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 8.2 | Very Positive | Score 7.9->8.2 (md 8->9, aam 9->10). External research cross-ref: undisputed #1 pharma AI — $1B NVIDIA co-innovation lab, 1016 Blackwell GPUs, $1.7B Isomorphic Labs deal, TuneLab platform, first $1T healthcare company |
| 2026-03-08 | 7.9 | Positive | Initial assessment from batch 3 research |
Healthcare Peers
Last researched: 2026-10-03
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.